` LMAT (LeMaitre Vascular Inc) vs S&P 500 Comparison - Alpha Spread

LMAT
vs
S&P 500

Over the past 12 months, LMAT has underperformed S&P 500, delivering a return of 1% compared to the S&P 500's 9% growth.

Stocks Performance
LMAT vs S&P 500

Loading
LMAT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
LMAT vs S&P 500

Loading
LMAT
S&P 500
Difference
www.alphaspread.com

Performance By Year
LMAT vs S&P 500

Loading
LMAT
S&P 500
Add Stock

Competitors Performance
LeMaitre Vascular Inc vs Peers

LeMaitre Vascular Inc
Glance View

Economic Moat
Narrow
Market Cap
1.8B USD
Industry
Health Care

LeMaitre Vascular Inc., a company engaged in the innovation and marketing of devices for vascular surgeons, traces its roots back to a family enterprise founded on the values of craftsmanship and precision. The company was established in 1983 by George LeMaitre, a preeminent vascular surgeon whose legacy continues to resonate within its core operations. Headquartered in Burlington, Massachusetts, LeMaitre Vascular specializes in developing and selling a variety of products designed to treat peripheral vascular disease. This encompasses conditions that affect blood vessels outside the heart and brain, such as aortic aneurysms and varicose veins. With devices like grafts, patches, and endovascular stent grafts, LeMaitre meets the need for effective surgical tools, facilitating procedures that enhance patient outcomes and surgical efficiency. The company generates revenue primarily through the sale and distribution of its diverse product line to hospitals and surgeons. LeMaitre Vascular leverages a direct sales model, hiring an adept sales force across the globe that builds strong relationships with clinicians. This direct approach is complemented by carefully selected distributors in regions less accessible by its direct sales teams. A key aspect of their strategy is constant innovation, where they thoughtfully assimilate advanced techniques and materials, frequently through strategic acquisitions of smaller firms with promising technologies. This dedication to development, alongside meticulous manufacturing processes, ensures that their offerings remain at the forefront of vascular surgery solutions, thereby sustaining financial growth and a robust competitive edge in a specialized market.

LMAT Intrinsic Value
58.39 USD
Overvaluation 29%
Intrinsic Value
Price
Back to Top